UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2023



.

P3 Health Partners Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) **001-40033** (Commission File Number) **85-2992794** (I.R.S. Employer Identification No.)

2370 Corporate Circle, Suite 300 Henderson, Nevada

(Address of principal executive offices)

89074 (Zip Code)

(702) 910-3950 (Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.0001 per share	PIII	The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of \$11.50	PIIIW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 🛛

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02. Results of Operations and Financial Condition.

On August 7, 2023, P3 Health Partners Inc. (the "Company") announced its financial results for the three and six months ended June 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Report").

The information in this Item 2.02, including the information contained in Exhibit 99.1 of this Report, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
<u>99.1</u>	Press Release of the Company, dated August 7, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

P3 Health Partners Inc.

Date: August 7, 2023

By: /s/ Atul Kavthekar

Atul Kavthekar Chief Financial Officer

P3 Health Partners Announces Second-Quarter 2023 Results

Management to Host Conference Call and Webcast August 7, 2023 at 4:30 PM ET

HENDERSON, NV—August 7, 2023—P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2023.

"The results for the second quarter of 2023 show the power and trajectory of the P3 model. I'm delighted to say we had solid improvement across all key metrics. The strength we have seen in 2023 has given us the stability and momentum to drive our next phase of success in 2024, and beyond," said Dr. Sherif Abdou, CEO of P3.

"We experienced approximately 1% medical cost trend for the quarter. That is a reflection of the effectiveness of P3's model and the increasing maturity of the membership on P3's platform. The value we deliver and demand for P3's model is rooted in our ability to bend the cost curve for our patients, providers, and payor clients," said Bill Bettermann, COO of P3.

Second-Quarter 2023 Financial Results

- Capitated revenue was \$325.6 million, an increase of 21.9% compared to \$267.1 million in the second quarter of the prior year
- Net loss was \$27.6 million, compared to a net loss of \$903.1 million in the second quarter of the prior year. The second quarter of 2022 was negatively impacted by a
 goodwill impairment charge of \$851.5 million
- Net loss PMPM was \$88 compared to a net loss PMPM of \$2,995 the second quarter of the prior year
- Adjusted EBITDA⁽¹⁾ was \$0.2 million, compared to an Adjusted EBITDA loss of \$28.7 million in the second quarter of the prior year
- Adjusted EBITDA PMPM⁽¹⁾ was roughly breakeven, compared to an Adjusted EBITDA loss PMPM of \$95 in the second quarter of the prior year
- · Gross profit was \$26.8 million, an improvement of \$24.8 million compared to \$2.0 million in the second quarter of the prior year
- · Gross profit PMPM was \$86, an improvement of \$79 compared to \$7 in the prior year
- Medical margin⁽¹⁾ was \$50.5 million, an increase of 132.1% compared to \$21.8 million in the second quarter of the prior year
- Medical margin PMPM⁽¹⁾ was \$161, an increase of 123.2% compared to a medical margin PMPM of \$72 in the prior year

First-Half 2023 Financial Results

- Capitated revenue was \$624.3 million, an increase of 16.3% compared to \$536.8 million in the first half of the prior year
- Net loss was \$80.0 million, compared to a net loss of \$963.9 million in the first half of the prior year. The first half of 2022 was negatively impacted by a goodwill
 impairment charge of \$851.5 million
- Net loss PMPM was \$129 compared to a net loss PMPM of \$1,613 in the first half of the prior year
- Adjusted EBITDA⁽¹⁾ loss was \$18.9 million, compared to an Adjusted EBITDA loss of \$47.6 million in the first half of the prior year
- Adjusted EBITDA PMPM⁽¹⁾ loss was \$30, compared to an Adjusted EBITDA loss of \$80 PMPM in the first half of the prior year

- · Gross profit was \$43.3 million, an improvement of 345% compared to \$9.7 million in the first half of the prior year
- Gross profit PMPM was \$70, an increase of 329% compared to \$16 in the first half of the prior year
- Medical margin⁽¹⁾ was \$89.7 million, an increase of 92.6% compared to \$46.6 million in the first half of the prior year
- Medical margin PMPM⁽¹⁾ was \$145, an increase of 85.9% compared to a medical margin PMPM of \$78 in the prior year

Full-Year 2023 Guidance

	Year Ending December 31, 2023					
	Low		High			
Medicare Advantage Members	 115,000		120,000			
Total Revenues (in millions)	\$ 1,200	\$	1,250			
Medical margin ⁽²⁾ (in millions)	\$ 155	\$	175			
Medical margin ⁽²⁾ PMPM	\$ 120	\$	130			
Adjusted EBITDA ⁽²⁾ Loss (in millions)	\$ (50)	\$	(30)			

(1) Adjusted EBITDA, Adjusted EBITDA per member, per month ("PMPM"), medical margin and medical margin PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures and more information regarding the Company's use of non-GAAP financial measures, please see the section titled "Non-GAAP Financial Measures" and the tables at the end of this press release.

⁽²⁾ The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA loss, medical margin and medical margin PMPM to net income (loss), gross profit and gross profit PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss), gross profit (loss) or gross profit (loss) PMPM because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) or gross profit (loss) PMPM because of the uncertainty around certain items that may impact net income (loss), gross profit (loss) or gross profit (loss) PMPM that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Non-GAAP Financial Measures" below.

Title & Webcast	P3 Health Second-Quarter Earnings Conference Call
Date & Time	August 7, 2023, 4:30pm Eastern Time
Conference Call Details	Toll-Free 1-877-270-2148 (US) International 1-412-902-6510 Ask to be joined into the P3 Health Partners call

The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the P3 website <u>ir.p3hp.org</u>). The Company's press release will be available on the Investor page of P3's website in advance of the conference call. An archived recording of the webcast will be available on the Investor page of P3's website for a period of 90 days following the conference call.

About P3 Health Partners (NASDAQ: PIII):

<u>P3 Health Partners Inc.</u> is a leading population health management company committed to transforming healthcare by improving the lives of both patients and providers. Founded and led by physicians, P3 has an expansive network of more than 2,600 affiliated primary care providers across the country. Our local teams of health care professionals manage the care of thousands of patients in 18 counties across five states. P3 supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, the P3 care team creates an enhanced patient experience by navigating, coordinating, and integrating the patient's care within the healthcare system. For more information, visit <u>www.p3hp.org</u> and follow us on LinkedIn and <u>Facebook.com/p3healthpartners</u>.

Non-GAAP Financial Measures

In addition to the financial results prepared in accordance accounting principles generally accepted in the U.S. ("GAAP"), this press release contains certain non-GAAP financial measures as defined by the SEC rules, including Adjusted EBITDA, Adjusted EBITDA PMPM, medical margin and medical margin PMPM. EBITDA is defined as GAAP net income (loss) before (i) interest, (ii) income taxes and (iii) depreciation and amortization. Adjusted EBITDA is defined as EBITDA, further adjusted to exclude the effect of certain supplemental adjustments, such as (i) mark-to-market warrant gain/loss, (ii) premium deficiency reserves, (ii) equity-based compensation expense and (vi) certain other items that we believe are not indicative of our core operating performances. Adjusted EBITDA PMPM is defined as Adjusted EBITDA divided by the number of Medicare Advantage members each month divided by the number of months in the period. We believe these non-GAAP financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other similar companies. Medical margin represents the amount earned from capitation revenue after medical claims expenses are deducted and medical margin PMPM is defined as medical margin divided by the number of Medicare Advantage members each month divided by the number of months in the period. Medical claims expenses represent costs incurred for medical services provided to our members. As our platform grows and matures over time, we expect medical margin to increase in absolute dollars; however, medical margin PMPM may vary as the percentage of new members brought onto our platform fluctuates. New membership added to the platform is typically dilutive to medical margin PMPM. We do not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In addition, other companies may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. The tables at the end of this press release present a reconciliation of Adjusted EBITDA to net income (loss) and Adjusted EBITDA PMPM to net income (loss) PMPM, and medical margin to gross profit and medical margin PMPM to gross profit PMPM, which are the most directly comparable financial measures calculated in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements address various matters, including the Company's future expected growth strategy and operating performance; current expectations regarding the Company's outlook as to revenue, at-risk Medicare Advantage membership, medical margin, medical margin PMPM and Adjusted EBITDA loss for the full year 2023, all of which reflect the Company's expectations based upon currently available information and data. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, our ability to continue as a going concern; our potential need to raise additional capital to fund our existing operations or develop and commercialize new services or expand our operations; our ability to achieve or maintain profitability; our ability to maintain compliance with our debt covenants in the future, or obtain required waivers from our lenders if future operating performance were to fall below current projections of if there are material changes to management's assumptions, we could be required to recognize non-cash charges to operating earnings for goodwill and/or other intangible asset impairment; our ability to identify and develop successful new geographies, physician partners, payors and patients; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to fund our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payers; the impact of COVID-19, including the impact of new variants of the virus, or another pandemic, epidemic or outbreak of infectious disease on our business and results of operation; increased labor costs; our

ability to recruit and retain qualified team members and independent physicians; and other factors discussed in Part I, Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 31, 2023, as updated by Part II, Item 1A. "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2023 to be filed with the SEC, and in the Company's other filings with the SEC. All information in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. You are cautioned not to place undue reliance on any forward-looking statements contained in this press release.

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts) (unaudited)

SSE D Control S Substrict Cash \$ \$9.924 \$ 17.37 Rearing cash 5.55 \$9.00 Headh plan receivable, net of allowner for cruft losses of \$150 and \$0, respectively 10.93 7.500 Propie dependes and other cructurat lasses 19.37 7.500 Propie dependes and other cructurat lasses 17.24, 40 100.062 Propie dependes and other cructurat lasses 7.601 8.515 DrAL CUREENT ASSETS 7.601 7.601 Drapher bases 7.624 8.505 Dranz CureEnt NASSETS 7.601 7.601 Drapher bases 7.624 8.505 Drapher bases 7.620 7.601 Drapher bases 7.601 7.601 <th></th> <th>June 30, 2023</th> <th>De</th> <th>cember 31, 2022</th>		June 30, 2023	De	cember 31, 2022
Cash\$\$\$7.37Festricit cash5.57920Health pian receivable, net of allowance for credit losses of \$150 and \$0, respectively102.48272.092Clinic fees, insurance and other receivable1.3377.300Prepaid expenses and other curvalues2.2132.648TOTAL CURRENT ASSETS9.010.929.535.105Other longering massis709.018755.105Other longering massis709.018755.105Other longering massis18.2715.950TOTAL ASSETS'9.068.9988.55.751LABLITIES'2.244116.6671.51.28CARENT LABLITIES'59.106511.542Accende spenses and other curval labilities2.247116.6611.51.388.224Health phase settements payable59.10651.51.207Chemina difficiency reserve1.51.381.50.071.51.207Accende depreses and other curval labilities1.51.801.51.2071.51.207Chemina difficiency reserve1.51.831.50.071.51.207Accende depreses and other curval labilities1.51.801.51.207Chemina difficiency reserve1.51.851.51.207Chemina difficiency reserve1.51.851.51.207Chemina difficiency reserve1.51.851.51.207Chemina difficiency reserve1.51.851.51.207Chemina difficiency reserve1.51.851.51.207Chemina difficiency reserve1.51.851.51.207Chemina	ASSETS	 		
Iscincia cain5.75900Headin plane receivable, not of allows of \$150 and \$0, respectively10.248272.000Propid sepanes and other receivable1.2377.500Propid sepanes and other receivable1.214100.0002Propid sepanes and other receivable9.2118.830Propid sepanes and other receivable9.2118.830Propid sepanes and other receivable9.2118.830Propid sepanes and other receivable18.27715.000Other Integretem asses18.27715.000CURRENT LIABLITIES.8.8209887.15.000CURRENT LIABLITIES.8.8209811.542Accound opposes and other current liabilities59.060\$Accound opposes and other current liabilities5.3311.542Accound opposes and other current liabilities5.33151.207Accound opposes and other current liabilities15.33151.207Accound opposes and other current liabilities29.50026.375Contar payable29.50024.664Accound oppose29.50024.664Operating and obstructures and other current liabilities11.064Accound oppose29.50024.575Contar planes and other current liabilities29.50024.575Accound oppose29.50024.575Contar planes and other current liabilities29.50024.575Contar current liabilities29.50024.575Contar current liabilities29.50035.158Contar	CURRENT ASSETS:			
Isaling nerocivable, net of allowance for credit losses of \$150 and \$0, respectively102,42972,002Clinic fees, insunance and other creterivable1,3717500Drepaid exgenses and other creterivable2,2112,2431TOTAL CURRENT ASSETS172,149100,602Poperty and exglingment, net799,018751,050Other long-resm asses18,27115,050Other long-resm asses18,27115,050CURRENT LABRILITES.\$908,599\$0,575,11CURRENT LABRILITES.2,21116,647Accred expenses and other current liabilities2,24116,647Accred expenses and other current liabilities2,24116,647Accred expenses and other current liabilities15,18882,243Clinic payable15,858151,207Pensiting diverses18,858143,068Clinic payable18,858143,068Clinic payable18,858143,068Clinic payable18,858143,061Clinic payable18,858143,061Clinic payable18,858143,061Clinic payable18,858143,061Conting extrema fination4,0074,974Lang-termine diverses2,5901,516Conting extrema fination4,0074,974Lang-termine diverses11,9761,518Conting extrema fination4,0074,974Lang-termine diverses11,8961,518Conting extrema fination6,7731,516Conting extrema fination	Cash	\$ 59,924	\$	17,537
Clinic Sex, insurance and other receivable19,377,500Prepaid expresses and other screet assets2,2312,643TOTAL CURRENT ASSETS102,149100,692Prepaid expresses and other screet assets9,5218,839Intanghe assets, net18,27115,950Other long-serm assets18,27115,950Intaghet assets18,27115,950Intaghet assets18,27115,950Intaghet assets18,27115,950Intaghet assets12,24116,647Concert asymptible2,1438,8224Accounts payable59,196\$Accound expresses and other current liabilities2,54313,508Accound expresses and other current liabilities2,54313,508Calcians payable5,87813,50814,502Accound expresses and other current liabilities15,82515,1207Presini deficiency reserve2,950326,37526,368Accound expresses and other current liabilities11,30614,664OrAL CURRENT LIABILITIES11,51211,51211,512Pressini deficiency reserve2,5901,51711,512Contingent consideration4,9074,7444,424TOTAL CURRENT LIABILITIES2,5901,51711,517Contingent consideration2,5901,51711,517Contingent consideration2,5901,51711,517Contingent consideration2,5901,51711,517Contingent consideration	Restricted cash	5,575		920
Prepare2.232.643TOTAL CURRENT ASSETS112,149100,092Poperty and equipment, net9,5218,839Intangble assets, net709,018751,050Oher long-term assets18,27115990TOTAL ASSETS ¹⁰ \$ 908,959\$ 967,571LARLITES, MEZZANINE EQUITY and STOCKHOLDERS' (DEFICIT EQUITY\$ 908,959\$ 967,571LARLITES, MEZZANINE EQUITY and STOCKHOLDERS' (DEFICIT EQUITY\$ 91,96\$ 11,522Accured expenses and other current labilities22,47116,647Accured expenses and other current labilities5,1388,8224Health plans settlements payable6,87813,608Accured expenses29,50326,575Accured expenses29,50326,575Accured expenses29,50326,575Accured expenses29,50326,575Accured expenses29,50326,575Accured expenses29,50326,575Accured expenses29,50326,575Accured expenses25,900241,664Operating Lass Etilements payable11,57611,517Contiger Consideration4,9074,794Long setter delt, net10,618.94,424TOTAL CURRENT LABILITIES11,51744Construct Consideration4,9074,794Long setter delt, net11,64744,647Construct Construct Setter Sette	Health plan receivable, net of allowance for credit losses of \$150 and \$0, respectively	102,482		72,092
TOTAL CURRENT ASSETS172,149100,692Property and equipment, net9,5218,839Intangbie assets700,018751,050Other long-term assets18,27115,090TOTAL ASSETS ⁽¹⁾ \$90,89,59\$\$LIABLITTES.\$90,89,59\$8,75,71LIABLITTES.CURRENT LIABLITTES:22,47116,647Accounts payable\$9,11,54215,1388,8224Locatic approxes and other current liabilities.15,1388,8224Liabli plans settlements payable6,87813,50815,203Claims payable.15,85815,207Premiun deficiency reserve.25,03326,375Accrured presers.11,56614,6041Operating lease liability.11,51611,516Ortal, CURRENT LIABLITTIES11,516TOTAL CURRENT LIABLITTIES11,516Operating lease liability.11,51611,51611,516Ortal, CURRENT LIABILITTESContingent considerationContingent considerationContingent considerationContingent consideration <td< td=""><td>Clinic fees, insurance and other receivable</td><td>1,937</td><td></td><td>7,500</td></td<>	Clinic fees, insurance and other receivable	1,937		7,500
Property and equipment, net9,5218,839Intanglio assets, net700,018751,050TOTAL ASSETS ¹⁰⁾ \$ 908,559\$ 876,571ILABLITES\$ 908,559\$ 876,571CURRENT LIABLITTES:Current liabilities22,47116,647Accured express and other current liabilities5,1388,224Current liabilities-5,1388,224Claims payable-5,1388,224Accured expressing other current liabilities-15,85215,207Premiu deficiency reserve-29,50326,375Operating East Elements payable-188,528151,207Continger Control East C	Prepaid expenses and other current assets	2,231		2,643
Intangible assets, net 70,018 751,059 Oher long-term assets 18,271 15,000 INTAL ASSETS ¹⁰ 908,059 § 876,571 LINEUTES. MEZZANKE EQUITY and STOCKHOLDERS' (DEFICIT) EQUITY 11,542 11,542 CACcounds payable 2,2,471 16,647 Accrued expenses and other current liabilities 2,2,471 16,647 Accrued expenses and other current liabilities 6,878 13,608 Accrued expenses and other current liabilities 6,878 13,608 Premium deficiency reserv 29,503 26,5375 Accrued expense and other current liabilities 11,926 11,150 Chaines payable 18,858 14,0601 Chaines payable 18,858 14,0601 Chaines payable 18,858 14,0601 Operating lease liability 11,176 11,516 Oracle current liabilities 25,903 26,5375 Contingent consideration 4,074 4,7041 Operating lease liability 11,976 11,516 Oracle current debt, net 10,818 <	TOTAL CURRENT ASSETS	 172,149		100,692
Other long-term assets 18,271 15,900 TOTA ASSETS ⁽⁷⁾ \$ 00,059 \$ 80,059 \$ 80,059 LABILITES.	Property and equipment, net	9,521		8,839
S 908,959 S 876,571 LABLITIES, MEZZANNE EQUITY and STOCKHOLDERS' (DEFICIT) EQUITY -	Intangible assets, net	709,018		751,050
Link Links, MEZZANNE EQUITY and STOCKHOLDERS' (DEFICIT) EQUITY CURRENT LIABILITIES: Accounds payable Accounds payable Accounds payable Accounds payable Accounds payable Accounds payable Claims payable Claims payable Claims payable Claims payable Claims payable Accrued payroll Health plans stelmennts payable Claims payable Accrued interest Operating lease liability Varrant liabilities Quarter time debt, net Constructures Constructures Quarter time debt, net Constructures Constructures Quarter time debt, net Constructures Class Constructures STOCKHOLDERS' (DEFICT) EQUITY: Class Constructures (14,000) Class Constructures Class Constructures Class Constructures Class Constructures Class Constructures Class Constructures C	Other long-term assets	18,271		15,990
CURRENT LIABILITIES: Accound spyable \$ 9,96 \$ 9,16,47 16,647 Accnued expense and other current liabilities 5,138 8,224 Health plans settlements payable 5,138 8,224 Itelalth plans settlements payable 158,528 151,007 Colums payable 29,503 26,575 Accrued expense 29,503 26,575 Colums payable 158,528 151,007 Accrued interest 11,966 14,661 TOTAL CURRENT LIABILITIES 250,400 241,664 Operating lease liability 11,976 11,517 Contingent consideration 4,907 4,794 Long-term debt, net 108,188 94,421 Long-term debt, net 108,188 94,421 COMUMEENTS AND CONTINCENCIES (Note 12) 353,912 353,912 MEZZANINE EQUITY: 20 20 Class A common sock, \$0001 par value; \$00,000 shares authorized; 114,958 shares issued and outstanding, respectively 11 4 Class A common sock, \$0001 par value; \$00,000 shares authorized; 14,959 shares issued and outstanding, respectively 20	TOTAL ASSETS ⁽¹⁾	\$ 908,959	\$	876,571
S 9,196 S 11,542 Accrued expenses and other current liabilities 22,471 16,647 Accrued exponses 5,138 8,224 Health plans settlements payable 6,878 13,608 Claims payable 158,528 151,207 Premium deficiency reserve 29,503 26,375 Accrued interest 18,686 14,061 TOTAL CURRENT LIABILITIES 250,000 241,664 Operating lease liability 11,796 11,516 Querating lease liability 11,796 11,516 Variant liabilities 2,599 1,517 Continger consideration 49,07 4,994 Long-term delv, net 109,188 94,421 TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMITMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 Redeemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class V common stock, \$0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively <td< td=""><td>LIABILITIES, MEZZANINE EQUITY and STOCKHOLDERS' (DEFICIT) EQUITY</td><td></td><td></td><td></td></td<>	LIABILITIES, MEZZANINE EQUITY and STOCKHOLDERS' (DEFICIT) EQUITY			
Accrued expenses and other current liabilities 22,471 16,647 Accrued expenses and other current liabilities 5,138 8,224 Health plans settlements payable 6,878 13,608 Claims payable 6,878 151,008 Premium deficiency reserve 29,503 26,375 Accrued interest 18,866 14,061 OrrAL CURRENT LLABILITIES 250,400 241,664 Operating lease liability 11,796 11,516 Warmat liabilities 2,599 1,517 Contingent consideration 4,907 4,9421 TOTAL CURRENT S AND CONTINGENCIES (Note 12) 377,890 353,912 COMMITTEMENTS AND CONTINGENCIES (Note 12) 4 44,21 TOTAL CURRENT S AND CONTINGENCIES (Note 12) 11 4 Class V common stock, \$,0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares sisued and outstanding, respectively 11 4 Class V common stock, \$,0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 12,389 315,375 315,375	CURRENT LIABILITIES:			
Accrued payroll 5,138 8,224 Health plans settlements payable 6,578 13,608 Clains payable 6,578 151,207 Premium deficiency reserve 29,503 26,375 Accrued interest 29,503 26,375 Accrued interest 18,686 144,061 TOTAL CURRENT LIABILITIES 250,400 241,664 Operating lease liability 11,796 11,516 Operating lease liability 2,599 1,517 Contingent consideration 2,599 1,517 Contingent consideration 4,907 4,734 Configent consideration 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 Reclemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class X common stock, \$,0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 612	Accounts payable	\$ 9,196	\$	11,542
Health plans settlements payable 6,878 13,608 Clains payable 158,528 151,207 Premium deficiency reserve 29,503 26,375 Accrued interest 29,503 26,375 TOTAL CURRENT LIABILITIES 20,000 241,664 Operating lease liability 20,900 241,664 Marrant liabilitying 20,900 241,664 Contingent consideration 11,796 11,516 Contingent consideration 4,907 4,794 Long-term debt, net 108,188 94,421 TOTAL LIABILITIES ^(I) 377,890 353,912 COMMITENTS AND CONTINGENCIES (Note 12) 377,890 353,912 MEZZANINE EQUITY: Class A common stock, \$0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class V common stock, \$0001 par value; 800,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 4 4 4 4 4 4 4 4 4 4 4 <td< td=""><td>Accrued expenses and other current liabilities</td><td>22,471</td><td></td><td>16,647</td></td<>	Accrued expenses and other current liabilities	22,471		16,647
Chains pable 158,528 151,207 Premium deficiency reserve 29,503 26,375 Accrued interest 18,686 14,061 Operating lesse liability 220,400 2241,664 Operating lesse liability 11,796 11,516 Warrant liabilities 2,599 1,517 Conjetern dob, net 108,188 944,211 TOTAL CURRENT LIABILITIES ⁽¹⁾ 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) 667,235 \$516,805 MEZZANINE EQUITY: 667,235 \$16,805 Redeemable non-controlling interest 667,235 \$16,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$0,001 par value; 205,000 shares and 41,579 shares issued and outstanding, respectively 11 4 Class A common stock, \$0001 par value; 205,000 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital (328,586) (308,545) Accumulated deficit (328,586) (308,545)	Accrued payroll	5,138		8,224
Premium deficiency reserve 29,503 26,375 Accend interest 18,686 14,061 TOTAL CURRENT LIABILITIES 2150,400 241,664 Operating lease liability 11,796 11,516 Warrant liabilities 2,599 1,517 Contingent consideration 4,907 4,794 Long-term debt, net 108,188 94,421 TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 MEZZANINE EQUITY: 667,235 516,805 Redeemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$0,001 par value; 800,000 shares authorized; 114,098 shares insued and outstanding, respectively 11 4 Class V common stock, \$0,001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 423,893 315,375 315,375 Accumulated defici (228,586) (309,545) (309,545) TOTAL LIABLITIEQUITY	Health plans settlements payable	6,878		13,608
Accrued interest 18,686 14,061 TOTAL CURRENT LIABILITIES 250,400 241,664 Operating lease liability 11,756 11,516 Warrant liabilities 2,599 1,516 Contingent consideration 2,690 4,794 Long-term debt, net 108,188 94,421 TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMITIMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 COMITIMENTS AND CONTINGENCIES (Note 12) 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class A common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 11 4 Class A common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital (328,586) (309,545) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	Claims payable	158,528		151,207
TOTAL CURRENT LIABILITIES 250,400 241,664 Operating lease liability 11,796 11,516 Warrant liabilities 2,599 1,517 Contingent consideration 2,690 4,794 Long-term debt, net 108,188 94,421 TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMITIMENTS AND CONTINGENCIES (Note 12) MEZZANINE EQUITY: 667,235 516,805 Redeemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 10 20 Additional paid in capital 129,2389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854 5,854	Premium deficiency reserve	29,503		26,375
Operating lease liability 11,796 11,516 Warrant liabilities 2,599 1,517 Contingent consideration 4,907 4,794 Long-term debt, net 108,188 944,217 TOTAL LIABILITIES ⁽¹⁾ 377,890 355,912 COMMITMENTS AND CONTINGENCIES (Note 12) 377,890 355,912 MEZZANINE EQUITY: 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class A common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 122,389 315,375 Accumulated deficit (238,586) (209,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (1136,166) 5,854 5,854	Accrued interest	 18,686		14,061
Warrant liabilities 2,599 1,517 Contingent consideration 4,907 4,794 Long-term deb, net 108,188 94,421 TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) 377,890 353,912 MEZZANINE EQUITY: 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 672,235 516,805 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class A common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 315,375 Accumulated deficit (328,586) (309,545) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (1136,166) 5,854 5,854	TOTAL CURRENT LIABILITIES	250,400		241,664
Contingent consideration 4,907 4,794 Long-term debt, net 108,188 94,421 TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) MEZZANINE EQUITY: Redeenable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 1 4 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class A common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 114,098 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 (328,586) (309,545) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854 5,854	Operating lease liability	11,796		11,516
Long-term debt, net 108,188 94,421 TOTAL LIABILITIES ^(h) 377,890 353,912 COMITIMENTS AND CONTINGENCIES (Note 12)	Warrant liabilities	2,599		1,517
TOTAL LIABILITIES ⁽¹⁾ 377,890 353,912 COMMITMENTS AND CONTINGENCIES (Note 12) MEZZANINE EQUITY: 667,235 516,805 Redeemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854 5,854	Contingent consideration	4,907		4,794
COMMITMENTS AND CONTINGENCIES (Note 12) MEZZANINE EQUITY: Redeemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	Long-term debt, net	 108,188		94,421
MEZZANINE EQUITY: 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY: 11 4 Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	TOTAL LIABILITIES ⁽¹⁾	377,890		353,912
Redeemable non-controlling interest 667,235 516,805 STOCKHOLDERS' (DEFICIT) EQUITY:	COMMITMENTS AND CONTINGENCIES (Note 12)			
STOCKHOLDERS' (DEFICIT) EQUITY: Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	MEZZANINE EQUITY:			
Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively 11 4 Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 20 Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	Redeemable non-controlling interest	667,235		516,805
Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively 20 Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	STOCKHOLDERS' (DEFICIT) EQUITY:			
Additional paid in capital 192,389 315,375 Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	Class A common stock, \$.0001 par value; 800,000 shares authorized; 114,098 shares and 41,579 shares issued and outstanding, respectively	11		4
Accumulated deficit (328,586) (309,545) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	Class V common stock, \$.0001 par value; 205,000 shares authorized; 198,505 shares and 201,592 shares issued and outstanding, respectively	20		20
TOTAL STOCKHOLDERS' (DEFICIT) EQUITY (136,166) 5,854	Additional paid in capital	192,389		315,375
	Accumulated deficit	 (328,586)		(309,545)
TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' (DEFICIT) EQUITY	TOTAL STOCKHOLDERS' (DEFICIT) EQUITY	 (136,166)		5,854
	TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' (DEFICIT) EQUITY	\$ 908,959	\$	876,571

(1) The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). As discussed in Note 13 "Variable Interest Entities," P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and amounts below refer only to VIEs held at the P3 LLC level. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the P3 LLC's VIEs totaling \$10.6 million and \$3.1 million as of June 30, 2023 and December 31, 2022, respectively, and total liabilities of onto include \$44.6 million and \$33.0 million of net amounts due to affiliates as of June 30, 2023 and December 31, 2022, respectively, as these are eliminated in consolidation and not presented within the condensed consolidated balance sheets. See Note 13 "Variable Interest Entities."

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited)

	Three Months	Ended Ju	ne 30,	Six Months E	nded J	une 30,
	2023		2022	2023		2022
OPERATING REVENUE:	 			 		
Capitated revenue	\$ 325,616	\$	267,102	\$ 624,320	\$	536,787
Other patient service revenue	3,470		2,352	6,843		6,211
TOTAL OPERATING REVENUE	329,086		269,454	 631,163		542,998
OPERATING EXPENSE:						
Medical expense	302,271		267,448	587,841		533,269
Premium deficiency reserve	(2,012)		(1,490)	3,128		(2,814)
Corporate, general and administrative expense	27,223		41,099	64,866		79,697
Sales and marketing expense	857		1,408	1,858		2,273
Depreciation and amortization	21,780		21,720	43,320		43,472
Goodwill impairment	 _		851,456	 _		851,456
TOTAL OPERATING EXPENSE	350,119		1,181,641	701,013		1,507,353
OPERATING LOSS	(21,033)		(912,187)	 (69,850)		(964,355)
OTHER INCOME (EXPENSE):						
Interest expense, net	(3,851)		(2,700)	(7,937)		(5,455)
Mark-to-market of stock warrants	(1,731)		11,815	(1,082)		5,954
Other	 (741)		(34)	 (645)		(40)
TOTAL OTHER EXPENSE	(6,323)		9,081	(9,664)		459
LOSS BEFORE INCOME TAXES	(27,356)	-	(903,106)	 (79,514)		(963,896)
PROVISION FOR INCOME TAXES	(226)		_	(516)		_
NET LOSS	(27,582)	-	(903,106)	 (80,030)		(963,896)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING						
INTEREST	(17,766)		(748,756)	(61,015)		(798,969)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST	\$ (9,816)	\$	(154,350)	\$ (19,015)	\$	(164,927)
NET LOSS PER SHARE (Note 9):						
Basic	\$ (0.09)	\$	(3.71)	\$ (0.25)	\$	(3.97)
Diluted	\$ (0.09)	\$	(3.73)	\$ (0.29)	\$	(4.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):						
Basic	107,454		41,579	74,699		41,579
Diluted	107,454		242,053	276,028		240,362

P3 HEALTH PARTNERS INC. and SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

		Six Months Ended June 30,		
		2023	2022	
CASH FLOWS FROM OPERATING ACTIVITIES:				
Net loss	\$	(80,030)	\$ (963,896)	
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization		43,320	43,472	
Equity-based compensation		2,008	15,427	
Goodwill impairment		_	851,456	
Amortization of original issue discount and debt issuance costs		340	—	
Accretion of contingent consideration		113	188	
Mark-to-market adjustment of stock warrants		1,082	(5,954)	
Premium deficiency reserve		3,128	(2,814)	
Changes in assets and liabilities:				
Health plan receivable		(30,540)	(49,555)	
Clinic fees, insurance, and other receivable		5,563	(376)	
Prepaid expenses and other current assets		139	1,890	
Other long-term assets		(1,289)	_	
Accounts payable, accrued expenses, and other current liabilities		1,924	1,163	
Accrued payroll		(3,086)	(3,041)	
Health plan settlements payable		(6,730)	(4,526)	
Claims payable		7,321	37,364	
Accrued interest		4,625	2,559	
Operating lease liability		(452)	3,555	
Net cash used in operating activities		(52,564)	(73,088)	
CASH FLOWS FROM INVESTING ACTIVITIES:				
Purchases of property and equipment		(1,652)	(1,401)	
Net cash used in investing activities		(1,652)	(1,401)	
CASH FLOWS FROM FINANCING ACTIVITIES:		() /	· · · · ·	
Proceeds from long-term debt, net of original issuance discount		14,102	_	
Proceeds from private placement offering, net of offering costs paid		87,329	_	
Repayment of long-term debt		_	(2,446)	
Payment of debt issuance costs		(173)		
Net cash provided by (used in) financing activities		101,258	(2,446)	
Net change in cash and restricted cash		47,042	(76,935)	
Cash and restricted cash, beginning of period		18,457	140,834	
Cash and restricted cash, end of period	\$,	\$ 63,899	
cash and restricted cash, end of period	4	00,199	- 35,699	

RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (LOSS)

(in thousands, except PMPM)

(unaudited)

	Three Months	Ended June 30,		Six Months E	nded June 30,
	2023	2022		2023	2022
		(in	thousan	ıds)	
Net loss	\$ (27,582)	\$ (903,10	6) \$	(80,030)	\$ (963,896)
Interest expense, net	3,851	2,70	0	7,937	5,455
Depreciation and amortization expense	21,780	21,72	20	43,320	43,472
Provision for income taxes	226	-		516	—
Mark-to-market of stock warrants	1,731	(11,81	5)	1,082	(5,954)
Premium deficiency reserve	(2,012)	(1,49	0)	3,128	(2,814)
Equity-based compensation	1,031	3,71	6	2,008	15,427
Transaction and other related costs ⁽¹⁾	—	8,01	0	70	9,112
Goodwill impairment	—	851,45	6	—	851,456
Other ⁽²⁾	1,192	14	3	3,053	149
Adjusted EBITDA (loss)	\$ 217	\$ (28,66	6) \$	(18,916)	\$ (47,593)
Adjusted EBITDA (loss) PMPM	\$ 1	\$ (9	5) \$	(30)	\$ (80)

(1) Transaction and other related costs during the six months ended June 30, 2023 consisted of legal fees incurred related to acquisition-related litigation.

(2) Other during the three and six months ended June 30, 2023 consisted of (i) interest income offset by (ii) cybersecurity incident loss, (iii) restructuring and other charges, including severance and benefits paid to employees pursuant to workforce reduction plans, (iv) the disposition of our Pahrump operations, (v) expenses for third-party consultants to assist us with the development, implementation, and documentation of new and enhanced internal controls and processes for compliance with Sarbanes-Oxley Section 404(b) with respect to the six months ended June 30, 2023, (vi) a legal settlement outside of the ordinary course of business with respect to the six months ended June 30, 2023, and (vii) valuation allowance on our notes receivable.

MEDICAL MARGIN (in thousands, except PMPM) (unaudited)

	Three Months Ended June 30,				Six Months E	nded Ju	ine 30,
	2023 2022				2023		2022
			(in tho	usands)			
Capitated revenue	\$ 325,616	\$	267,102	\$	624,320	\$	536,787
Less: medical claims expense	(275,121)		(245,344)		(534,579)		(490,202)
Medical margin	\$ 50,495	\$	21,758	\$	89,741	\$	46,585
Medical margin PMPM	\$ 161	\$	72	\$	145	\$	78

RECONCILIATION OF GROSS PROFIT TO MEDICAL MARGIN (in thousands) (unaudited)

	Three Months Ended June 30,				ie 30,		
	2023		2022		2023		2022
			(in tho	usands)			
Gross profit ⁽¹⁾	\$ 26,815	\$	2,006	\$	43,322	\$	9,729
Other patient service revenue	(3,470)		(2,352)		(6,843)		(6,211)
Other medical expense	27,150		22,104		53,262		43,067
Medical margin	\$ 50,495	\$	21,758	\$	89,741	\$	46,585

(1) Effective for the quarter ended June 30, 2023, we modified the method by which we reconcile medical margin. Previously, we reconciled medical margin to operating loss as the most directly comparable measure calculated in accordance with GAAP. In the current period and on a go-forward basis we will reconcile to gross profit as we have determined that gross profit is the most directly comparable GAAP measure.

Contacts

Investor Relations

Karen Blomquist Vice President, Investor Relations P3 Health Partners kblomquist@p3hp.org

Kassi Belz Executive Vice President, Communications P3 Health Partners (904) 415-2744 kbelz@p3hp.org